Overview

AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events. This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Criteria
Inclusion Criteria:

- Patients at least 35 years of age with a diagnosis of Acute Exacerbation of Chronic
Bronchitis (AECB) and decision taken by the investigator to treat with Avelox.

Exclusion Criteria:

- Exclusion criteria must be read in conjunction with the local product information.